Exclusive interview for SPINOFF.COM with Attila Hajdu, CEO and Founder of Stelvio Therapeutics, about innovative treatments for glioblastoma multiforme (GBM), the most common and lethal brain tumor Stelvio Therapeutics has developed a novel approach to therapy, which aims to induce the differentiation of tumor cells into normal cells providing an attractive alternative to Temozolomide (TMZ) as the first line treatment for GBM. The team of Stelvio Therapeutics is doing this with a powerful imaging and machine learning screening technology, which will discover small molecule drugs that mimic the differentiation effect of serum and bone morphogenic proteins (BMPs). Their strategy is to induce the differentiation of tumor cells instead of trying to kill them. Thus, an epigenetic signature platform called Microscopic Imaging of Epigenetic Landscape (MIEL) was invented to accelerate the discovery and development of compounds that drive differentiation of cancer (lat. Carcinoma) stem cells into benign cell types.